Navigation Links
FDA Clears the Way for Generic Versions of Transdermal Patches to Treat Chronic Pain

The Food and Drug Administration (FDA) has granted approval to Mylan Technologies, Inc., for the first generic version of Alza Corporation's Duragesic Patch (Fentanyl Transdermal System) used to treat patients suffering from severe chronic pain that cannot be managed with alternative analgesics. When applied to the skin, this patch technology delivers fentanyl, an opioid pain medication that is slowly absorbed into the body through the skin providing pain relief for up to three days (72 hours).

The agency's approval is expected to provide patients with access to a lower cost alternative of this pain management system. At the same time that FDA approved Mylan's generic product, it acted on several citizens' petitions requesting that FDA deny or delay approval of the product.

The original Fentanyl Transdermal System was approved in August 1990. It is currently approved for the management of chronic pain in patients who require continuous opioid analgesia for pain that cannot be managed by acetaminophen-opioid combinations, non-steroidal analgesics, or as needed dosing with short-acting opioids.

Fentanyl is currently a Schedule II controlled substance, which is the highest level of control for drugs with a recognized medical use. As a controlled substance in Schedule II of the Controlled Substances Act (CSA), Fentanyl also comes under the jurisdiction of the Drug Enforcement Administration (DEA), which administers the CSA. Schedule II drugs are subject to manufacturing quotas set by DEA with input on medical need from FDA, distribution tracking, import and export controls, registration of prescribers and dispensers, and written prescriptions without refills.


'"/>

Source:FDA


Page: 1

Related biology news :

1. Prescription Drug Patches Gaining Ground, Tackling New Therapies
2. Discovery Could Lead To Novel Approaches In HIV Treatment
3. New Treatment Rivals Chemotherapy For Lymphoma, Study Finds
4. FDA Approves New Drug to Treat Type I and Type II Diabetes
5. Rush Physicians Using Gene Therapy For Heart Patients With Moderate To Severe Chest Pains Who Do Not Benefit From Other Treatments
6. Ophthalmologists Use Artificial Silicon Retina Microchip To Treat Vision Loss
7. Effective Cancer Treatments Follow The Clock
8. Potential Drug Target For Treating Cocaine Abuse Found
9. Protein Discovery Could Unlock The Secret To Better TB Treatment
10. Embryonic Stem Cells Treated With Growth Factor Reverse Hemophilia In Mice: UNC Researchers
11. Natural Killers Could Lead to New Hepatitis Treatments
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/30/2017)... March 30, 2017  On April 6-7, 2017, Sequencing.com ... Genome hackathon at Microsoft,s headquarters in ... will focus on developing health and wellness apps that ... Hack the Genome is the first hackathon for ... world,s largest companies in the genomics, tech and health ...
(Date:3/29/2017)... -- higi, the health IT company that operates the largest ... , today announced a Series B investment from BlueCross ... new investment and acquisition accelerates higi,s strategy to create ... health activities through the collection and workflow integration of ... and secures data today on behalf of over 36 ...
(Date:3/24/2017)... The Controller General of Immigration from Maldives Mr. Mohamed Anwar ... prestigious international IAIR Award for the most innovative high security ePassport and ... ... Maldives Immigration Controller General, Mr. Mohamed ... the right) have received the IAIR award for the "Most innovative high ...
Breaking Biology News(10 mins):
(Date:9/21/2017)... Paramus, New Jersey (PRWEB) , ... September 21, ... ... for highly-regulated pharmaceutical and clinical research sector professionals, has announced the addition of ... CFR Part 11 training - Compliance with Regulation 21 CFR Part 11 ...
(Date:9/20/2017)... ... 20, 2017 , ... Cybrexa Therapeutics , a start-up ... role of chief scientific officer. In this role, Dr. Paralkar will lead the ... CEO, Per Hellsund. , “I was impressed with Cybrexa’s revolutionary technology and excellent ...
(Date:9/20/2017)... ... September 20, 2017 , ... From industry leaders, sports stars, ... standard medicine failed. Many of these people had lost all hope. Their ... Free Download (pdf) , “Neil takes readers on a riveting journey ...
(Date:9/19/2017)... Philadelphia, PA (PRWEB) , ... September 19, 2017 ... ... are joining Philadelphia’s largest group of funded early-stage tech companies. “Grit” author Angela ... anchor tenant. Also joining the ic@3401 community is Cooley, an international law firm ...
Breaking Biology Technology: